Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | FPA150 |
Synonyms | |
Therapy Description |
FPA150 (Alsevalimab) is a human monoclonal antibody against B7-H4 that promotes immune checkpoint inhibition and antibody-dependent cell-mediated cytotoxicity (Ann Oncol, 28 (suppl_5), Sep 2017, abstract 6PD). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FPA150 | FPA-150|FPA 150|Alsevalimab | Immune Checkpoint Inhibitor 147 | FPA150 (Alsevalimab) is a human monoclonal antibody against B7-H4 that promotes immune checkpoint inhibition and antibody-dependent cell-mediated cytotoxicity (Ann Oncol, 28 (suppl_5), Sep 2017, abstract 6PD). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03514121 | Phase I | FPA150 | FPA150 in Patients With Advanced Solid Tumors | Completed | USA | 1 |